#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12020	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2201	543.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1679	1679	T	666	T	600	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12020	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2201	543.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1413	1413	C	706	C	659	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3524	637.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1676	1676	A	766	A	700	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3524	637.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2310	2310	C	722	C	664	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3524	637.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2384	2384	A	677	A,G	622,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22546	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3524	637.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2936	2936	C	690	C,A	640,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1788	folP	855	855	100.0	folP.l15.c4.ctg.1	1450	122.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1002	1004	AGC	168;168;170	A;G;C	154;154;158	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4736	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	142.1	1	SNP	p	S91F	1	.	.	271	273	TTC	517	519	TTC	170;170;171	T;T;C	154;157;159	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4736	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	142.1	1	SNP	p	D95G	1	.	.	283	285	GGC	529	531	GGC	167;169;168	G;G;C	159;158;157	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4736	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	142.1	1	SNP	p	G95N	0	.	.	283	285	GGC	529	531	GGC	167;169;168	G;G;C	159;158;157	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1470	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1279	114.1	1	SNP	p	G45D	0	.	.	133	135	GGC	398	400	GGC	200;200;200	G;G;C	183;182;183	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	700	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	850	81.5	0	.	n	.	0	A197.	DEL	197	197	A	497	497	A	180	A	160	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1458	1460	GTC	160;159;160	G;T;C	150;150;151	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	1	SNP	p	D86N	0	.	.	256	258	GAC	564	566	GAC	183;182;182	G;A;C	164;162;164	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	1	SNP	p	R87W	0	.	.	259	261	CGT	567	569	CGT	182;184;182	C;G;T	166;165;163	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	1	SNP	p	S87R	1	.	.	259	261	CGT	567	569	CGT	182;184;182	C;G;T	166;165;163	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	1	SNP	p	R87I	0	.	.	259	261	CGT	567	569	CGT	182;184;182	C;G;T	166;165;163	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4368	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2977	146.3	1	SNP	p	S88P	0	.	.	262	264	TCC	570	572	TCC	181;182;183	T;C;C	161;163;163	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3854	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2795	137.5	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1445	1447	TGC	180;182;182	T,C;G;C	158,1;161;160	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3854	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2795	137.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1655	1657	GGC	183;182;182	G;G;C,A	168;164;163,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1267	1269	GCA	190;192;193	G;C;A	171;174;179	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1270	1272	ATC	196;196;196	A;T;C	175;179;177	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1282	1284	GTG	194;193;192	G;T;G	175;175;178	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1282	1284	GTG	194;193;192	G;T;G	175;175;178	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1786	1788	ACC	202;200;200	A;C;C	176;178;177	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1840	1842	GCG	204;200;200	G,C;C,G;G	174,1;158,1;163	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1840	1842	GCG	204;200;200	G,C;C,G;G	174,1;158,1;163	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1963	1965	GGC	174;171;172	G;G;C,A	160;158;157,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1972	1974	GGC	175;171;172	G;G;C	160;154;157	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3622	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2393	150.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1990	1992	TCG	184;189;186	T,G;C;G	136,10;168;159	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5096	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3209	158.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1686	1688	CCG	210;211;212	C;C;G,T	189;190;187,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2080	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1811	114.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	589	589	C	138	C	124	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	332	334	GAA	189;189;190	G;A;A	177;180;179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	0	.	p	.	0	N134D	NONSYN	400	402	AAT	620	622	GAT	236;234;230	G;A;T	208;208;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	743	745	TCA	209;210;211	T;C;A	198;200;201	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	872	874	GTC	219;218;217	G;TCCCC,TCCC;C	205;205,1;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1202	1204	GCA	167;171;170	G;C;A	148;152;150	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	1	SNP	p	G120K	1	.	.	358	360	AAG	578	580	AAG	230;231;233	A;A;G	207;207;210	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	1	SNP	p	A121D	1	.	.	361	363	GAC	581	583	GAC	236;234;235	G;A,G;C	213;211,1;212	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2426	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1412	170.3	1	SNP	p	D121N	0	.	.	361	363	GAC	581	583	GAC	236;234;235	G;A,G;C	213;211,1;212	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	272	porB3	990	116	92.24	porB3.l15.c17.ctg.2	488	24.0	0	.	p	.	0	M18T	NONSYN	52	54	ATG	355	357	ACG	56;53;49	A;C;G	49;47;44	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	272	porB3	990	116	92.24	porB3.l15.c17.ctg.2	488	24.0	0	.	p	.	0	T29A	NONSYN	85	87	ACC	388	390	GCC	52;51;48	G;C,T;C	45;42,1;42	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	272	porB3	990	116	92.24	porB3.l15.c17.ctg.2	488	24.0	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	397	399	CAA	31;31;31	C;A;A	26;27;27	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	272	porB3	990	116	92.24	porB3.l15.c17.ctg.2	488	24.0	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	403	405	TAC	17;17;17	T;A;C	17;17;17	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8398	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4864	172.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2020	2022	AAT	208;210;209	A;A;T	189;189;188	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	904	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	886	100.8	1	SNP	p	V57M	1	.	.	169	171	ATG	437	439	ATG	176;176;178	A;T;G	167;166;167	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
